Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, biomanufacturing and upgraded business modeling to secure the human healthcare and biosafety
Traditionally a disease has been defined by its clinical presentation and observable characteristics, not by the underlying molecular mechanisms, pathways and systems biology-related processes specific to a particular patient (ignoring persons-at-risk). A new systems approach to subclinical and/or diseased states, being based on principles of systems biology and achievements of design-driven translational applications resulted in a new trend in the healthcare services, namely, personalized and precision medicine (PPM).
To achieve the implementation of PPM concept in Bioindustry & Clinical Practice, it is necessary to create a fundamentally new strategy based upon the biomarkers and targets to have the unique impact. In this sense, despite breakthroughs in research that have led to an increased understanding of PPM-based human disease, the translation of discoveries into therapies for patients has not kept pace with medical need. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the patients and persons-at-risk resulting in improved outcomes and more cost effective use of the latest health care resources including diagnostic (companion ones), preventive and therapeutic (targeted molecular and cellular) etc.
And across worldwide basic, translational, clinical, and applied design-driven research, and throughout the industrial trends, scientific breakthroughs have been the launching point for principal bioproduct- and biotool developments in the translational trajectory. Even the most innovative healthcare technologies being translated in the right direction, would provide patient benefits only when adopted by clinicians and/or patients in actual practice. So, co-development between innovation-related builders and customers is a key agile principle. And in the coming wave of innovation in the broad-scope applications, learning rapidly what new bioproduct features work well for clinicians and patients will become even more crucial.